Massimo Breccia

Massimo Breccia

UNVERIFIED PROFILE

Are you Massimo Breccia?   Register this Author

Register author
Massimo Breccia

Massimo Breccia

Publications by authors named "Massimo Breccia"

Are you Massimo Breccia?   Register this Author

100Publications

2584Reads

8Profile Views

Maintenance therapy in AML: The past, the present and the future.

Am J Hematol 2019 Nov 11;94(11):1254-1265. Epub 2019 Sep 11.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25620DOI Listing
November 2019

Ponatinib: A Review of Efficacy and Safety.

Curr Cancer Drug Targets 2018 ;18(9):847-856

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009617666171002142659DOI Listing
September 2019

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.

Bone Marrow Transplant 2019 Sep 18. Epub 2019 Sep 18.

Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0683-1DOI Listing
September 2019

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Ann Hematol 2019 Aug 11;98(8):1891-1904. Epub 2019 May 11.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03706-xDOI Listing
August 2019

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Ann Hematol 2019 Aug 5;98(8):1919-1925. Epub 2019 Jun 5.

Hematology, Department of Precision and Translational Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03724-9DOI Listing
August 2019

A journey through infectious risk associated with ruxolitinib.

Br J Haematol 2019 Aug 29. Epub 2019 Aug 29.

Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16174DOI Listing
August 2019

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.

Hematol Oncol 2019 Jul 19. Epub 2019 Jul 19.

Hematology, Department of Translational and Precision Medicine, University 'Sapienza' and Policlinico Umberto 1, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2650DOI Listing
July 2019

Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data.

Authors:
Massimo Breccia

Acta Haematol 2019 21;142(2):61-63. Epub 2019 May 21.

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, "Sapienza" University, Rome, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496449DOI Listing
May 2019

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Ther Adv Hematol 2019 1;10:2040620719826444. Epub 2019 Mar 1.

Haematology, Department of Cellular Biotechnologies and Haematology, Azienda Ospedaliera, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Roma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719826444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399752PMC
March 2019

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Expert Rev Hematol 2019 Feb 7;12(2):81-87. Epub 2019 Jan 7.

a Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562332DOI Listing
February 2019

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

Ann Hematol 2018 Oct 27;97(10):1803-1808. Epub 2018 May 27.

Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3375-9DOI Listing
October 2018

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Br J Haematol 2018 08 5;182(3):427-429. Epub 2017 Jul 5.

Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14783DOI Listing
August 2018

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Clin Drug Investig 2018 05;38(5):475-476

Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-018-0623-7DOI Listing
May 2018

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol 2018 04 17;181(2):275-278. Epub 2017 Feb 17.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14560DOI Listing
April 2018

Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.

Expert Rev Hematol 2018 04 13;11(4):301-306. Epub 2018 Mar 13.

a Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, 'Sapienza' University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1451322DOI Listing
April 2018

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.

Curr Oncol Rep 2018 03 6;20(3):23. Epub 2018 Mar 6.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, 'Sapienza' University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0669-yDOI Listing
March 2018

Are chronic myeloid leukemia patients ready to stop long-term treatment?

Leuk Lymphoma 2017 12 23;58(12):2976-2978. Epub 2017 May 23.

b Data Center and Health Outcomes Research Unit , Italian Group for Adult Hematologic Diseases (GIMEMA) , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1330476DOI Listing
December 2017

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.

Am J Hematol 2017 Dec 19;92(12):E661-E664. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24913
Publisher Site
http://dx.doi.org/10.1002/ajh.24913DOI Listing
December 2017

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Am J Hematol 2017 12 19;92(12):E668-E670. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24916DOI Listing
December 2017

Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.

Expert Rev Mol Diagn 2017 11 26;17(11):1001-1008. Epub 2017 Sep 26.

a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2017.1383156DOI Listing
November 2017

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Health Qual Life Outcomes 2017 Oct 18;15(1):204. Epub 2017 Oct 18.

Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-017-0788-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648464PMC
October 2017

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

J Clin Oncol 2017 Feb 31;35(6):605-612. Epub 2016 Oct 31.

Uwe Platzbecker, Christian Thiede, Christoph Röllig, and Gerhard Ehninger, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden; Uwe Platzbecker and Gerhard Ehninger, Study Alliance Leukemia, Dresden; Walter Fiedler, University Hospital Hamburg-Eppendorf; Norbert Schmitz, Asklepios Klinik St Georg Hamburg, Hamburg; Peter Brossart, Innere Medizin mit deSchwerpunkten Onkologie, Haematollogie un Rheumatologie, Bonn; Bernd Hertenstein, Klinikum Bremen Mitte, Bremen; Helmut R. Salih, University Hospital Tubingen; Mohammed Wattad, Kliniken Essen Süd, Essen; Michael Lübbert, University Medical Center, Freiburg; Christian H. Brandts, Goethe University Frankfurt, Frankfurt; Mathias Hänel, Klinikum Chemnitz gGmbH, Chemnitz; Hartmut Link, Klinik für Innere Medizin I, Westpfalz-Klinikum, Kaiserslautern; Konstanze Döhner, Hartmut Döhner, and Richard F. Schlenk, University Hospital Ulm, Ulm; Arnold Ganser, Hannover Medical School, Hannover, Germany; Giuseppe Avvisati, University Campus Bio-Medico; Laura Cicconi, Mariadomenica Divona, Sergio Amadori, and Francesco Lo-Coco, University Tor Vergata; Francesca Paoloni, Marco Vignetti, Fabio Efficace, Paola Fazi, and Franco Mandelli, Gruppo Italiano Malattie Ematologiche dell'Adulto Central Office; Marco Vignetti and Massimo Breccia, Sapienza University, Rome; Felicetto Ferrara, Cardarelli Hospital, Naples; Francesco Albano, University of Bari, Bari; Marco Sborgia, U.O. di Ematologia Clinica, Pescara; Eros Di Bona, San Bortolo Hospital, Vicenza; Erika Borlenghi, U.O. di Ematologia, Spedali Civili, Brescia; Roberto Cairoli, Ospedale Niguarda, Ca' Granda, SC Ematologia; Agostino Cortelezzi, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milano; Alessandro Rambaldi, Azienda Opsedaliera Papa Giovanni XXIII, Bergamo; Lorella Melillo, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo; Giorgio La Nasa, Centro Trapianti Midollo Osseo, Ospedale R. Binaghi, Università di Cagliari, Cagliari; Chiara Frairia, Hematology, Città della Salute e della Scienza, Torino; Enrico Maria Pogliani, Ospedale San Gerardo, Università degli Studi Milano Bicocca, Monza; Claudio Fozza, University of Sassari, Sassari; Alfonso Maria D'Arco, U.O. Medicina Interna e Onco-Ematologica P.O. "Umberto I," Nocera Inferiore, Nocera Inferiore; Nicola Di Renzo, Ospedale Vito Fazzi, Lecce; and Francesco Fabbiano, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1982DOI Listing
February 2017

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.

Expert Rev Hematol 2017 Feb 12;10(2):155-159. Epub 2017 Jan 12.

a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1273766DOI Listing
February 2017

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Am J Hematol 2017 Jan 12;92(1):37-41. Epub 2016 Nov 12.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology and Clinical Oncology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24572DOI Listing
January 2017

Second line small molecule therapy options for treating chronic myeloid leukemia.

Expert Opin Pharmacother 2017 Jan 9;18(1):57-65. Epub 2016 Dec 9.

a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1267141DOI Listing
January 2017

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Expert Opin Drug Saf 2016 16;15(4):525-33. Epub 2016 Feb 16.

a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2016.1145654DOI Listing
December 2016

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Support Care Cancer 2016 12 23;24(12):4887-4894. Epub 2016 Jul 23.

Department of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-016-3344-6DOI Listing
December 2016

Current first- and second-line treatment options in acute promyelocytic leukemia.

Int J Hematol Oncol 2016 Nov 2;5(3):105-118. Epub 2017 Feb 2.

Hematology, Department of Cellular Biotechnologies & Hematology, Sapienza University, Via Benevento 6, 00161 Rome, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/ijh-2016-0010
Publisher Site
http://dx.doi.org/10.2217/ijh-2016-0010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171971PMC
November 2016

Early molecular response in chronic myeloid leukemia and halving time: Latest evidences.

Leuk Res 2016 09 1;48:20-5. Epub 2016 Jul 1.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.06.010DOI Listing
September 2016

Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?

Curr Med Res Opin 2016 08 12;32(8):1453-4. Epub 2016 May 12.

b Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2016.1185399DOI Listing
August 2016

How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.

Expert Opin Pharmacother 2016 Aug 3;17(11):1517-26. Epub 2016 Jun 3.

a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1190335DOI Listing
August 2016

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.

Br J Haematol 2016 07 28;174(1):160-2. Epub 2015 Oct 28.

Department of Haematology and Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13758DOI Listing
July 2016

Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol 2016 06 25;173(6):945-6. Epub 2015 Aug 25.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13649DOI Listing
June 2016

Current standard treatment of adult acute promyelocytic leukaemia.

Br J Haematol 2016 Mar 21;172(6):841-54. Epub 2015 Dec 21.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13890DOI Listing
March 2016

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib.

Mediterr J Hematol Infect Dis 2016 20;8(1):e2016016. Epub 2016 Feb 20.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2016.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771144PMC
March 2016

Ponatinib in chronic myeloid leukaemia: ready for first-line?

Lancet Haematol 2015 Sep 30;2(9):e352-3. Epub 2015 Jul 30.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome 00161, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00130-1DOI Listing
September 2015